Emil Kuriakose, MD

Trials

Studies that name Emil Kuriakose, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:46 UTC. Open this list on ClinicalTrials.gov

• N/A
  NCT04698681 · NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial

  Calithera Biosciences, Inc · terminated · Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung · study director
• Ph2
  NCT04265534 · KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC

  Calithera Biosciences, Inc · terminated · Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung · study director
• Ph1/Ph2
  NCT03965845 · A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

  Calithera Biosciences, Inc · completed · Solid Tumors, NSCLC, CRC · study director
• Ph1
  NCT02903914 · Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

  Incyte Corporation · completed · Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC) · study director

Grants

NIH projects from RePORTER, fetched 2026-11-12 12:46 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.